Arbutus Biopharma Corp Common Stock, Value, Issued
Arbutus Biopharma Corp (ABUS) had Common Stock, Value, Issued of $1.45 billion as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:CommonStockValue · last filed 2026-08-12
- 2013-12-31: Common Stock, Value, Issued 216.70M CAD.
- 2012-12-31: Common Stock, Value, Issued 181.79M CAD; Common Stock, Value, Issued as first filed 238.25M CAD.
- 2011-12-31: Common Stock, Value, Issued 233.50M CAD.
- 2010-12-31: Common Stock, Value, Issued 229.49M CAD.
CAD
| Period end | Common Stock, Value, Issued | Common Stock, Value, Issued as first filed |
|---|---|---|
| 2013-12-31 | 216.70M CAD 10-K · filed 2014-03-28 | |
| 2012-12-31 | 181.79M CAD 10-K · filed 2014-03-28 | 238.25M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 233.50M CAD 20-F · filed 2013-03-27 | |
| 2010-12-31 | 229.49M CAD 20-F · filed 2012-03-27 |
USD
| Period end | Common Stock, Value, Issued |
|---|---|
| 2026-06-30 | $1.45B 10-Q · filed 2026-08-12 |
| 2026-03-31 | $1.44B 10-Q · filed 2026-05-13 |
| 2025-12-31 | $1.42B 10-Q · filed 2026-08-12 |
| 2025-09-30 | $1.42B 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.42B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $1.42B 10-Q · filed 2025-05-14 |
| 2024-12-31 | $1.41B 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.41B 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.40B 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.38B 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.35B 10-K · filed 2025-03-27 |
| 2023-09-30 | $1.35B 10-Q · filed 2023-11-07 |
| 2023-06-30 | $1.34B 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.34B 10-Q · filed 2023-05-04 |
| 2022-12-31 | $1.32B 10-K · filed 2024-03-05 |
| 2022-09-30 | $1.31B 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.30B 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.30B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.29B 10-K · filed 2023-03-02 |
| 2021-09-30 | $1.07B 10-Q · filed 2021-11-04 |
| 2021-06-30 | $1.02B 10-Q · filed 2021-08-05 |
| 2021-03-31 | $1.01B 10-Q · filed 2021-05-05 |
| 2020-12-31 | $985.94M 10-K · filed 2022-03-03 |
| 2020-09-30 | $965.37M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $916.07M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $911.10M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $898.53M 10-K · filed 2021-03-04 |
| 2019-09-30 | $884.62M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $884.62M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $882.14M 10-Q · filed 2019-05-06 |
| 2018-12-31 | $879.40M 10-K · filed 2020-03-05 |
| 2018-09-30 | $878.80M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $878.19M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $876.29M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $876.11M 10-K · filed 2019-03-07 |
| 2017-09-30 | $876.05M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $873.84M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $870.85M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $867.39M 10-K · filed 2018-03-16 |
| 2016-09-30 | $864.38M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $861.15M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $840.48M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $834.24M 10-K · filed 2017-03-22 |
| 2015-09-30 | $828.58M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $821.66M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $814.44M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $290.00M 10-K · filed 2016-03-09 |
| 2014-09-30 | $288.36M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $284.79M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $283.64M 10-Q · filed 2014-05-14 |
| 2013-12-31 | $216.70M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |